Predictive value of CD24 and CD44 for neoadjuvant chemotherapy response and prognosis in primary breast cancer patients
-
- 堀口 和美
- Department of Human Pathology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan Department of Surgery, Cancer and Infectious Diseases Center of Tokyo Metropolitan Komagome Hospital Tokyo, Japan
-
- Toi Masakazu
- Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
-
- Horiguchi Shin-ichiro
- Department of Human Pathology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan Department of Pathology, Cancer and Infectious Diseases Center of Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
-
- Sugimoto Masahiro
- Institute for Advanced Biosciences, Keio University, Kanagawa, Japan Systems Biology Program, Graduate School of Media and Governance, Keio University, Kanagawa, Japan
-
- Naito Yasuhiro
- Institute for Advanced Biosciences, Keio University, Kanagawa, Japan Systems Biology Program, Graduate School of Media and Governance, Keio University, Kanagawa, Japan Department of Environment and Information Studies, Keio University, Kanagawa, Japan
-
- Hayashi Yukiko
- Department of Pathology, Cancer and Infectious Diseases Center of Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
-
- Ueno Takayuki
- Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
-
- Ohno Shinji
- Department of Breast Oncology, National Hospital Organization Kyusyu Cancer Center, Fukuoka, Japan
-
- Funata Nobuaki
- Department of Pathology, Cancer and Infectious Diseases Center of Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
-
- Kuroi Katsumasa
- Department of Surgery, Cancer and Infectious Diseases Center of Tokyo Metropolitan Komagome Hospital Tokyo, Japan
-
- Tomita Masaru
- Institute for Advanced Biosciences, Keio University, Kanagawa, Japan Systems Biology Program, Graduate School of Media and Governance, Keio University, Kanagawa, Japan Department of Environment and Information Studies, Keio University, Kanagawa, Japan
-
- 江石 義信
- Department of Human Pathology, Tokyo Medical and Dental University Graduate School, Tokyo, Japan
この論文をさがす
抄録
Purpose: We investigated the significance of CD24 and CD44 expression for predicting responses to chemotherapy and prognosis in primary breast cancer patients. Patients and Methods: Diagnosis of breast cancer was confirmed by core needle biopsy, and immunohistochemical studies were performed. Preoperatively, patients received anthracyclinecontaining chemotherapy. Expression of CD44 and CD24 was assessed immunohistochemically and the relationship with chemotherapy response and with prognosis was analyzed. Results : Between 2001 and 2004, 139 women were enrolled in this study. In the correlation analysis, CD24 expression was negatively associated with pathological response to chemotherapy (p=0.0003). A machine learning technique with an alternating decision tree (ADTree) showed that four logical rules are involved in predicting the response depending on the combination of CD24, HER2, tumor stage, CD44, progesterone receptor, and patient age. In the survival analysis, patients having CD44 (++) showed a significantly favorable prognosis as compared with others (p=0.0002). A multivariate analysis showed that CD44 expression had an independent prognostic value (p<0.001). Conclusion : We found a significant correlation between CD44 expression and prognosis and between CD24 expression and response to chemotherapy. CD24 and CD44 expressions would be useful predictive markers, although further studies are needed.
収録刊行物
-
- Journal of Medical and Dental Sciences
-
Journal of Medical and Dental Sciences 57 (2), 165-175, 2010
国立大学法人 東京医科歯科大学
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390282680495531520
-
- NII論文ID
- 110007617721
-
- NII書誌ID
- AA12028964
-
- ISSN
- 21859132
- 13428810
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- IRDB
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可